David Larish

The High Court has agreed to hear Otsuka's appeal of a decision that revoked its Abilify patent extension, which Otsuka argued would “lead to a groundswell of court proceedings”.

Pharmacor wants to amend its defence in AstraZeneca's suit over the Australian drug maker's plans to launch a generic version of diabetes drug Forxiga so that it can argue a patent extension for the drug should not have been granted.

AstraZeneca has won an interlocutory injunction barring Pharmacor from making a generic version of its blockbuster diabetes drug Forxiga while a patent case over the drug proceeds.

After years of pre-trial stoushes, a trademark dispute over Russian vodka has worn a Federal Court judge's patience thin, with the judge remarking that the court was entitled to expect better from the litigants.

The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.

Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea. 

After losing a fight over access to millions of seized documents, Fortescue has settled its trade secrets case against green iron company Element Zero.

A judge has declined to order US-based animal genomics company Scidera to file a position statement in its bovine gene patent infringement suit and said she was “running out of patience” after unsuccessful strike-out and summary dismissal applications by the defendants.

Andrew ‘Twiggy’ Forrest’s Fortescue can't get access to nine million seized documents in its trade secrets spat against green iron start-up Element Zero.

Green iron startup Element Zero is challenging a bid by Fortescue for access to nine million seized documents in their trade secrets spat, saying its rival has not met the test for proving inadequate discovery of material.